$62.25
1.983.29%
Últ. Act.: Oct 20, 4:00 PM
$62.25
1.983.29%
Royalty Pharma (RPRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.27 | $1.19 | $1.33 | $1.07 |
| Actual | $1.32 | $1.30 | $1.47 | $1.17 |
| Surprise | +3.94% | +9.24% | +10.5% | +9.35% |
| Revenue | ||||
| Estimate | $795.3M | $877.5M | $832.6M | $779.4M |
| Actual | $674.0M | $631.0M | $622.0M | $609.0M |
| Surprise | -15.3% | -28.1% | -25.3% | -21.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.18 | $1.52 | $0.78 | $0.32 |
| Revenue | ||||
| Consensus | $883.1M | $935.5M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $1.32 | $1.27 | 3.94 % |
| Q1 | May 6, 2026 | $1.30 | $1.19 | 9.24 % |
| Q4 | Feb 11, 2026 | $1.47 | $1.33 | 10.5 % |
| Q3 | Nov 5, 2025 | $1.17 | $1.07 | 9.35 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $674.00M | $795.30M | -15.3 % |
| Q1 | May 6, 2026 | $631.00M | $877.54M | -28.1 % |
| Q4 | Feb 11, 2026 | $622.00M | $832.62M | -25.3 % |
| Q3 | Nov 5, 2025 | $609.00M | $779.42M | -21.9 % |